åêðáéäåõóçó γ.ν.α.

528 Βιταμίνη D-διφωσφονικά νεότερης γενιάς
Nov;42(11):1228-36.
23. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa)
induced avascular necrosis of the jaws: a growing epidemic.
J Oral Maxillofac Surg. 2003;61(9):1115-7.
24. Μigliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated
osteonecrosis of mandibular and maxillary
bone. An emerging oral complication of supportive cancer
therapy. Cancer 2005;104(1):83-93.
25. Migliorati CA, Siegel MA, Elting LS. Bisphosphonateassociated
osteonecrosis: a long-term complication
of bisphopshonate treatment. Lancet Oncol. 2006
Jun;7(6):508-14.
26. Khan A. Osteonecrosis of the jaw: new developments
in an old disease. J Rheumatol 2008;35(4):547-9.
27. Rosen CJ, Hochberg MC, Bonnick SL et al. Treatment
with once-weekly alendronate 70 mg compared with
onceweekly risedronate 35 mg in women with postmenopausal
osteoporosis: a randomized double-blind
study. J Bone Mineral Res 2005;20(1):141-51.
28. Miller PD, Epstein S, Sedarati F et al. Once-monthly
oral ibandronate compared with weekly oral alendronate
in postmenopausal osteoporosis. Curr Med Res
2008;24:207-13.
29. Reginster JY. Efficacy and tolerability of once-monthly
oral ibandronate in postmenopausal osteoporosis: 2
year results from the MOBILE study. Ann Rheum Dis.
2006;65(5):654-61.
30. Bonnick S. Comparison of weekly treatment of postmenopausal
osteoporosis with alendronate versus
risedronate over two years. J Clin Endocrinol Metab
2006;91(7): 2631-7.
31. Byrjalsen I. Bone turnover and bone collagen maturation
in osteoporosis: effects of antiresorptive therapies.
Osteoporos Int 2008;19(3):339-48.
32. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic
acid and clinical fractures and mortality after hip
fracture. N Engl J Med. 2007;357(18):1799-1809.
33. Rizzoli R. Two-year results of once-weekly administration
of alendronate 70 mg for the treatment of postmenopausal
osteoporosis. J Bone Miner Res. 2002;17(11):1988-
96.
34. Harris ST. Two-year efficacy and tolerability of risedronate
once a week for the treatment of women with
postmenopausal osteoporosis. Curr Med Res Opin.
2004;20(5):757-64.
35. Lyles KW, Colσn-Emeric CS, Magaziner JS et al. Zoledronic
acid and clinical fractures and mortality after hip
fracture. N Engl J Med. 2007;357(18):1799-809.
36. Black DM. Once-Yearly Zoledronic Acid for Treatment
of Postmenopausal Osteoporosis. N Engl J Med
2007;356(18):1809-22.
37. Tonino RP, Meunier PJ, Emkey R et al. Skeletal benefits
of alendronate: 7-year treatment of postmenopausal
osteoporotic women. J Clin Endocrinol Metab.
2000;85(9):3109-15.
38. Reginster J, Minne HW, Sorensen OH et al. Randomized
trial of the effects of risedronate on vertebral fractures in
women with established postmenopausal osteoporosis.
Vertebral Efficacy with Risedronate Therapy (VERT) Study
Group. Osteoporos Int. 2000;11(1):83-91.
39. Harris ST, Watts NB, Genant HK et al. Effects of risedronate
treatment on vertebral and nonvertebral fractures
in women with postmenopausal osteoporosis:
a randomized controlled trial. Vertebral Efficacy With
Risedronate Therapy (VERT) Study Group. JAMA.
1999;282(14):1344-52.
40. Kanis JA, Burlet N, Cooper C et al. European guidance for
the diagnosis and management of osteoporosis in postmenopausal
women. Osteoporos Int. 2008;19(4):399-
428.
41. Liberman UA, Hochberg MC, Geusens P et al. Hip and
non-spine fracture risk reductions differ among antiresorptive
agents: Evidence from randomised controlled
trials. Int J Clin Pract. 2008;62(1):164-5.
xxxxxxxxxxx
xxxxxx